Homburger advised Santhera on its reverse share split

Santhera Pharmaceuticals Holding has completed a 10:1 reverse split of its shares, which had been approved by the shareholders on June 27, 2023, with the listing and first day of trading of the post-split shares on the SIX Swiss Exchange.

The transaction was enabled by a rule change that made reverse splits much easier for Swiss public companies after January 1, 2023. The new shares issued after the reverse stock split will receive a new International Securities Identification Number (ISIN), while the existing shares held prior to the reverse stock split will be cancelled. For technical reasons, shareholders who wish to continue to exercise their voting rights are requested to arrange for re-registration in the Company’s share register.

The Homburger team was led by partner Daniel Häusermann (corporate / m&a, capital markets, pictured) and included Stefan Oesterhelt (tax), Jasmin Künzle and Martin Cattaneo (both corporate / m&a, capital markets) as well as Eduard De Zordi and Philipp Klein (both capital markets).